EuroSciCon Conference on

Clinical Cardiology and Cardiovascular Disease

Theme: Leading edge in the field of Cardiology

Event Date & Time

Event Location

London, UK

16 years of lifescience communication

Performers / Professionals From Around The Globe

Tracks & Key Topics

Clinical Cardiology 2018

About Conference

The EuroSciCon will be holding its CPD accredited for Clinical Cardiology and Cardiovascualr Disease  May 24-26, 2018 London, UK. The theme of this year’s meeting is "Leading edge in the field of Cardiology" which will provide an international platform for discussion of present and future challenges in cardiac diseases, prevention and treatment of myocardial abnormalities, new inventions in technology. World-leading health practitioners, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and emerging research.

What’s New?

Cardiology Conferences includes international attendee workshops, lectures and symposia, including a designated registration area, a refreshment break and gala lunch.  Cardiologists, Cardiovascular researchers can join the Clinical Cardiology and Cardiovascualr Disease EuroSciCon as an international member to receive discounts on registration. So come and join the leading experts and allied professionals in the International Cardiology Conferences from May 24-26  2018 in London, UK to keep up with the rapidly accelerating pace of change that is already having an impact on the field clinical cardiology and will continue to in the future.

EuroSciCon is the longest running independent life science events company with a predominantly academic client base. Our multi-professional and multi-speciality approach creates a unique experience that cannot be found with a specialist society or commercially.


Euroscicon are corporate members of the following organisations

Royal Society of Biology


British Society for Immunology

Rare Care UK

Opportunities for Conference Attendees

For Researchers &Faculty:

Speaker Presentations

Poster Display

Symposium hosting

Workshop organizing

For Universities, Associations & Societies:

Association Partnering

Collaboration proposals

Academic Partnering

Group Participation

For Students & Research Scholars:

Poster Competition (Winner will get Best Poster Award)

Young Researcher Forum (YRF Award to the best presenter)

Student Attendee

Group registrations


For Business Delegates:

Speaker Presentations

Symposium hosting

Book Launch event

Networking opportunities

Audience participation

For Companies:

Exhibitor and Vendor booths

Sponsorships opportunities

Product launch

Workshop organizing

Scientific Partnering

Marketing and Networking with clients

Euroscicon organizes International Nutrition Meetings annually across Europe, Austria, Ireland, Germany, France, Liechtenstein, Lithuania, Finland, Luxembourg, Hungary, Italy, Norway, Poland, Denmark, Macedonia, Greece, Portugal, Romania, Czech Republic, Switzerland, United Kingdom, Belgium, Scotland, Latvia, Ukraine, Sweden, Denmark, Spain, Netherlands Russia, Bulgaria, France, with solitary subject of quickening logical revelations.


Why London?

London is the capital and most populous city of England and the United Kingdom. Standing on the River Thames in the south east of the island of Great Britain, London has been a major settlement for two millennia. Since at least the 19th century, "London" has also referred to the metropolis around this core, historically split between Middlesex, Essex, Surrey, Kent, and Hertfordshire, which today largely makes up Greater London, governed by the Mayor of London and the London Assembly. London is the world's leading investment destination, hosting more international retailers and ultra-high-net-worth individuals than any other city. London's universities form the largest concentration of higher education institutes in Europe, and a 2014 report placed it first in the world university rankings. London has a diverse range of people and cultures, and more than 300 languages are spoken in the region. It’s estimated mid-2015 municipal population was 8,673,713, the largest of any city in the European Union, and accounting for 12.5 per cent of the UK population. London's urban area is the second most populous in the EU, after Paris, with 9,787,426 inhabitants at the 2011 census. The iconic ‘Big Ben’ clock tower and Westminster Abbey, site of British monarch coronations. Across the Thames River, the London Eye observation wheel provides panoramic views of the South Bank cultural complex, and the entire city.

Sessions & Tracks

Cardiovascular Disease:

Cardiovascular diseases are universal cause leading to increased mortality. This is worldwide fact except in Africa. Together they resulted in 17.9 million deaths (32.1%) in 2015 up from 12.3 million (25.8%) in 1990. Deaths, at a given age, due to cardiovascular diseases are more common and have been increasing in much of the developing countries, while rates have declined in most of the developed countries since 1970s. Coronary artery disease and stroke constitute for 80% of CVD deaths in males and 75% of CVD deaths in females. Most cardiovascular disease affects older adults. In the United States 11% of people between 20 and 40 suffer from CVD, while 37% between 40 and 60, 71% of people between 60 and 80, and 85% of people over 80 have CVD. The average count of deaths from coronary artery disease in the developed world is around 80 years of age while it is around 68 years in the developing world. Disease onset is generally seven to ten years earlier in men as compared to women.

  • Atherosclerosis
  • Coronary artery disease
  • Cardiomyopathy
  • Transient ischemic attacks( angina pectoris and myocardial infarction)
  • Cardiac defects in pregnancy

Cardiac Medications:

Cardiovascular drugs are used to treat the abnormal conditions of heart or circulatory system or vascular system. They are a group of complicated drugs which are used to treat multiple heart conditions. Cardiac medications are used to increase the blood supply and to decrease the work load on the heart. This sub-topic includes alpha, beta blockers, angiotensin II receptor blockers, dual antiplatelet therapy, ACE inhibitors, digoxin preparations, diuretics and vasodilators. There are 120 Companies in USA that are making Cardiac Therapeutic Agents in Cardiology. Around 6 new drugs were introduced in 2015 and 2 drugs were introduced in 2016. There are many types of cardiovascular drugs in the market that include Corlanor (ivabradine), Kanuma (sebelipase alfa), Byvalson (nebivolol and valsartan), and Yosprala (aspirin and omeprazole).

  • Alpha and beta blockers
  • Angiotensin-II receptor blockers
  • Dual antiplatelet therapy
  • Angiotensin converting enzyme inhibitors
  • Digoxin preparations, diuretic and vasodilators

Pediatric Cardiology:

Pediatric Cardiology plays a major role in the diagnosis of congenital heart defects, performing diagnostic procedures such as echocardiograms, cardiac catheterizations, and for the ongoing management of the sequel of heart disease in infants, children and adolescents. The inclined graph of neonates with congenital heart defects referred to the neonatal intensive care unit reflects the increasing awareness that the defects may be present. Chest radiography and ECG rarely used in the neonatal diagnosis. Congestive heart failure in the fetus, or hydrops, can be detected by performing fetal echocardiography. Nursing and care for pediatric cardiac patients also plays an important role for the cure of pediatric cardiac patients.

  • Patent ductus arteriosus
  • Atrial septal defect
  • Hypoplastic left heart syndrome
  • Pediatric cardiac tumors
  • Specific congenital heart defects

Heart as Functional Syncytium:

Heart is a major muscular organ in humans and animals. It plays a crucial role in supply of blood, a fluid connective tissue to the various parts of the body. It provides the body with oxygen and nutrients and also directs in the removal of metabolic wastes. Heart is divided into four chambers: upper left and right atria and lower left and right ventricles. Heart consists of heart valves which prevent the backflow. The wall of heart consists of three layers namely epicardium, endocardium and myocardium. The heart pumps the blood with the help of a rhythm proposed by a group of pacemaking cells in sinoatrial node. This causes contraction of heart and generates a current which travels along the conduction system of heart. During this process the blood low in oxygen enters the heart where the oxygen is used and gets metabolized to carbon dioxide and is transferred to lungs.

  • Pathways of veins, arteries and capillaries
  • Thermoregulation
  • Protection from infections
  • Hormonal delivery

Cardiac Surgeries:

The surgeries done on the vessels of heart by the cardiac surgeons are known as cardiac surgery. Cardiac surgeries are implemented to treat ischemic heart diseases, congenital heart diseases, rheumatic heart disease including endocarditis. It also includes heart transplantation. Cardiopulmonary bypass techniques has reduced the mortality rates of these surgeries to relatively low ranks. Coronary artery bypass grafting (CABG) is the most common type of heart surgery. CABG improves blood flow to the heart. Surgeons use CABG to treat people who have severe coronary heart disease (CHD).

  • Open heart surgery
  • Coronary artery bypass grafting
  • Transmyocardial laser revascularization
  • Cardiothoracic Surgery
  • Pediatric cardiovascular surgery

Congenital Heart Block:

Congenital heart block is a rare disorder which has an occurrence of about 1 in 22,000 live births. The underlying cause for congenital heart block is any disturbances in the transfer of electrical nerve impulses that regulate the normal rhythmic, pumping action of cardiac muscle. If the transmission of the electrical signal is obstructed, the blocked transmission is known as heart block or AV block. If the blockade occurs in fetus or new born then the condition is known as congenital heart block. Thus condition neither alters the flow of blood nor cause any blockage or damage to the major or minor coronary arteries.

  • Neonatal lupus syndrome
  • Congenital heart block in adults
  • Fetal heart block in pregnancy
  • Congenital heart block with sjoren syndrome

Cardiac Remodeling:

Cardiac remodeling also known as ventricular remodeling is defined as altered genomic expression leading to molecular, cellular and interstitial changes which cause changes in shape, size, structure and function of the heart. Cardiac myocyte is the major cell involved in cardiac remodeling. The underlying cause for cardiac remodeling may be physiological or pathological remodeling, cardiac load, hemodynamic load, neurohumoral activation. Chronic hypertension, valvular heart disease, congenital heart disease may also lead to cardiac remodeling. Cardiac remodeling may further lead to myocardial necrosis and disproportionate thinning of heart.

  • Hypertensive ventricular remodeling
  • Atrial remodeling
  • Reverse cardiac modeling
  • Medication for cardiac remodeling

Advanced devices used to treat Cardiac Diseases:

Cardiac diseases can be treated with the help of various implantable devices. Individuals suffering with serious arrhythmias and heart blocks are the subjects for implantable defibrillators. People with heart failure develop abnormal conduction of the heart’s electrical system that changes the regular rhythms of heart. Cardiac resynchronization therapy, also known as biventricular pacing, serves as one of the method for cardiac treatment. A left ventricular assist device (LVAD) is a battery-operated, mechanical pump-type device which is implanted in the body surgically. Coronary artery bypass surgery diverts the blood supply around a blocked section of the artery. During this procedure, surgeons isolate healthy blood vessels from another part of the body, such as a leg or the chest wall. They then surgically attach the vessels to the diseased artery in such a way that the blood can flow around the blocked section.

  • Left ventricular assist device
  • Implantable cardioverter defibrillators
  • Cardiac resynchronization therapy
  • Intra-aortic balloon pump (IABP)

Cardiovascular Genetics:

The recent and rapid development of molecular genetics in cardiovascular diseases has created a new understanding of their pathogenesis and natural history, and also new possibilities for the diagnosis of these genetic disorders through genetic testing. This has induced new expectations, and new demands, from both families and physicians regarding genetic counselling, DNA testing and application of this knowledge in clinical practice. A new task for cardiologists is therefore to integrate these data in order to give the most relevant information to the patients and the relatives, to discuss genetic testing, and to use the data to optimise the management of the family. At the same time the various impacts of genetic management such as psychological, social, ethical and legal issues should be recognised, anticipated and taken into account. This is possible through a close collaboration between cardiologists and members of other medical or non‐medical disciplines such as geneticists, genetic counsellors, psychologists, and molecular biologists.

  • Genetics of Congenital Heart Disease
  • Genetic epidemiology and translational cardiovascular genomics\
  • Cardiovascular Endocrinology
  • Genetic Cardiomyopathies
  • Genetic Epidemology

Stem Cell Therapy in Cardiology:

Heart failure is a condition in which the heart is not able to pump enough blood throughout the body for its normal function. The cause of this can be either functional or structural disorder of the heart. Common causes of heart failure include cardiomyopathy, hypertension, heart valve problems and coronary artery disease. There is no heart failure cure. With respect to the heart, stem cells have the ability to not only home into the damaged areas but also to initiate a cascade of biological events which both culminate in healing of the heart muscle. For example, animal studies have demonstrated that stem cell therapy will cause new muscle cells to be formed through stimulation of dormant stem cells that are already inside the heart muscle. In these studies, the administered stem cell also transformed into new heart muscle cells.

  • Heart stem surgery
  • Stem cell heart regeneration
  • Stem cell therapy for congestive heart failure
  • Current status of cell therapy in cardiomyopathy

Invasive Techniques for Diagnosis and Treatment:

Invasive diagnostic and therapeutic techniques are indispensable for the diagnosis and interventional treatment of coronary artery disease, valvular involvement and, in particular, if the specific components of the inflammatory or degenerative processes in rheumatic disease are to be identified in the different components of the heart. Although impairment of cardiac function and ischaemia can be suspected also by non-invasive techniques, coronary involvement needs the final proof by angiography. Endomyocardial or epicardial biopsy identifies the key players of autoreactivity: the infiltrating cells and the bound and circulating antibodies. Before corticoid treatment is started, a viral or microbial aetiology has to be excluded at the site of cardiac inflammation. This again can only be done by the analysis of cardiac tissue samples.

  • Left and right catheterization and angiography
  • Endomyocardial biopsy
  • Pericardiocentesis and pericardiopsy
  • Epicardial and pericardial biopsy

Non Invasive Imaging:

Non-invasive cardiac imaging is mostly used to detect the presence of any heart disease. Recently, with advancements in imaging technology, non-invasive imaging has also been used for the detection of presence, severity and prognosis of the cardiac disease. Cardiac magnetic resonance imaging is a non-invasive tool to evaluate congenital heart disease in children and adults. Coronary CT angiography and MRI of coronary arteries provide an anatomical assessment of coronary stenosis, whereas the hemodynamic significance of a coronary artery stenosis can be assessed by stress myocardial perfusion imaging.

  • Functional imaging
  • Anatomical imaging
  • Stress echocardiography
  • Positron emission tomography

Nano-technology in Cardio science:

The field of nanotechnology is growing explosively and impinging on all walks of life. Nanotechnology proved to be promising to improve the diagnosis and treatment of heart, lung and blood diseases. Nanotechnology-based local drug delivery has the potential to achieve restenosis prevention while not impeding endothelial healing. Molecularly targeted drugs can be aimed to specifically bind to epitopes in the injured media and adventitia. Nanotechnology can be used in the imaging of atherosclerosis, detection of vulnerable plaque and treatment of vascular stenosis.

  • Nano-carriers against atherosclerotic plaques
  • Polysaccharide Nano systems for Future Progress in Cardiovascular Diseases
  • Transmyocardial Revascularization (TMR) by Medical Nanomaterial
  • Nano Artificial Heart Valve Surgery
  • Nanotechnology for Cardiac Tissue Regeneration

Current research in Cardiology:

Cardiac research is been included as a sub topic in cardiology conferences. This sub topic serves as a platform to exchange new advanced and innovative ideas related to the field of cardiology and search for the optimized techniques to improve cardiac health.  There are 50 associations and societies and the main association for Interventional cardiology in USA. 120 universities are working on Current Research in Cardiology. Some of the  current research topics in cardiology includes; Electrophysiology and Arrhythmia Research, Myocardial and Heart Failure Research.

  • Neuro cardiology
  • Cardiac complications with endocrinal disorders
  • Cardiovascular diseases with obesity
  • Cardiovascular diseases with breast cancer


Media Partners/Collaborator/Sponsors

A huge thanks to all our amazing partners. We couldn’t have a conference without you!

Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker
Conference Speaker